Adaptive Biotechnologies Corporation

NasdaqGS:ADPT 株式レポート

時価総額:US$692.1m

Adaptive Biotechnologies マネジメント

マネジメント 基準チェック /24

Adaptive Biotechnologiesの CEO はChad Robinsで、 Sep2009年に任命され、 の在任期間は 15.17年です。 の年間総報酬は$ 8.90Mで、 7.4%給与と92.6%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の1.23%を直接所有しており、その価値は$ 8.51M 。経営陣と取締役会の平均在任期間はそれぞれ6.2年と8.8年です。

主要情報

Chad Robins

最高経営責任者

US$8.9m

報酬総額

CEO給与比率7.4%
CEO在任期間15.2yrs
CEOの所有権1.2%
経営陣の平均在職期間6.2yrs
取締役会の平均在任期間8.8yrs

経営陣の近況

Recent updates

Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Nov 01
Does Adaptive Biotechnologies (NASDAQ:ADPT) Have A Healthy Balance Sheet?

Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Oct 05
Market Participants Recognise Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Revenues Pushing Shares 27% Higher

Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Jul 12
Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) Share Price Could Signal Some Risk

Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

May 08
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?

It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Apr 03
It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks

Adaptive Biotechnologies: A Post Earnings Assessment

Feb 25

Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Feb 17
Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically

Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Feb 01
Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%

Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Nov 17
Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Oct 13
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Jul 06
Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?

Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

May 05
Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding

We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Apr 15
We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely

Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Dec 13
Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system

Oct 11

Adaptive Biotechnologies announces $250M non-dilutive royalty financing

Sep 12

We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Aug 14
We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate

Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth

Apr 29
Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth

Adaptive Biotechnologies: Good Buy For Long-Term Investors

Apr 15

Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?

Feb 26
Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?

We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth

Jan 09
We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth

CEO報酬分析

Adaptive Biotechnologies の収益と比較して、Chad Robins の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2024n/an/a

-US$195m

Jun 30 2024n/an/a

-US$213m

Mar 31 2024n/an/a

-US$215m

Dec 31 2023US$9mUS$663k

-US$225m

Sep 30 2023n/an/a

-US$196m

Jun 30 2023n/an/a

-US$191m

Mar 31 2023n/an/a

-US$195m

Dec 31 2022US$9mUS$658k

-US$200m

Sep 30 2022n/an/a

-US$221m

Jun 30 2022n/an/a

-US$232m

Mar 31 2022n/an/a

-US$229m

Dec 31 2021US$9mUS$639k

-US$207m

Sep 30 2021n/an/a

-US$190m

Jun 30 2021n/an/a

-US$171m

Mar 31 2021n/an/a

-US$155m

Dec 31 2020US$7mUS$597k

-US$146m

Sep 30 2020n/an/a

-US$122m

Jun 30 2020n/an/a

-US$99m

Mar 31 2020n/an/a

-US$82m

Dec 31 2019US$3mUS$493k

-US$70m

Sep 30 2019n/an/a

-US$62m

Jun 30 2019n/an/a

-US$56m

Mar 31 2019n/an/a

-US$53m

Dec 31 2018US$3mUS$423k

-US$46m

報酬と市場: Chadの 総報酬 ($USD 8.90M ) は、 US市場 ($USD 3.17M ) の同規模の企業の平均を上回っています。

報酬と収益: Chadの報酬は増加しましたが、会社は利益を上げていません。


CEO(最高経営責任者

Chad Robins (50 yo)

15.2yrs

在職期間

US$8,904,267

報酬

Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Chad Robins
Co-Founder15.2yrsUS$8.90m1.23%
$ 8.5m
Julie Rubinstein
President & COO6.8yrsUS$2.97m0.32%
$ 2.2m
Harlan Robins
Co-Founder & Chief Scientific Officer15.2yrsUS$8.61m0.69%
$ 4.8m
Sharon Benzeno
Chief Commercial Officer of Immune Medicine6.8yrsUS$2.88m0.22%
$ 1.5m
Christopher Carlson
Founderno dataデータなしデータなし
Kyle Piskel
VP, CFO & Principal Accounting Officer3.1yrsUS$1.66m0.10%
$ 723.8k
Karina Calzadilla
Vice President of Investor Relationsno dataデータなしデータなし
Francis Lo
Chief People Officer5.6yrsデータなし0.17%
$ 1.2m
Susan Bobulsky
Chief Commercial Officer of MRD4.3yrsデータなし0.17%
$ 1.2m
Mary Lancelotta
Senior Vice President of MRD BioPharma1.2yrsデータなしデータなし

6.2yrs

平均在職期間

50yo

平均年齢

経験豊富な経営陣: ADPTの経営陣は経験豊富で経験豊富です(平均在職期間は6.2年)。


取締役

名称ポジション在職期間報酬所有権
Chad Robins
Co-Founder15.2yrsUS$8.90m1.23%
$ 8.5m
Peter Neupert
Lead Independent Director10.9yrsUS$355.00k0.093%
$ 647.1k
H. Parker
Member of Corporate Advisory Boardno dataデータなしデータなし
Michelle Griffin
Independent Director5.7yrsUS$330.00k0.035%
$ 243.6k
Robert Hershberg
Independent Director11.8yrsUS$325.00k0.051%
$ 356.3k
Michael Pellini
Independent Director6.8yrsUS$310.00k0.037%
$ 254.6k
Carol Gallagher
Member of Corporate Advisory Boardno dataデータなしデータなし
Craig Weissman
Member of Corporate Advisory Boardno dataデータなしデータなし
Graham Allen
Member of Corporate Advisory Boardno dataデータなしデータなし
Matthew Kahn
Member of Corporate Advisory Boardno dataデータなしデータなし
Katey Owen
Independent Director3.7yrsUS$310.00k0.038%
$ 263.2k

8.8yrs

平均在職期間

58.5yo

平均年齢

経験豊富なボード: ADPTの 取締役会経験豊富 であると考えられます ( 8.8年の平均在任期間)。